| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30058638 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS30020716 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS30058639 | HIV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS20036587 | HPV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
| TVIS20023553 | HPV | ENSG00000169313.10 | protein_coding | P2RY12 | No | No | 64805 | Q9H244 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | P2RY12 |
|---|---|
| DrugBank ID | DB15163 |
| Drug Name | Selatogrel |
| Target ID | BE0000110 |
| UniProt ID | Q9H244 |
| Regulation Type | antagonist |
| PubMed IDs | 32056160 |
| Citations | Schilling U, Dingemanse J, Ufer M: Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Clin Pharmacokinet. 2020 May;59(5):545-566. doi: 10.1007/s40262-020-00864-4. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(=NC(=N1)C1=CC=CC=C1)N1CC[C@@H](C1)OC |
| Pathways | |
| PharmGKB | |
| ChEMBL |
